title: Development and in vitro characterization of drug delivery system of rifapentine for osteoarticular tuberculosis.
abstract: The study was to develop and evaluate the rifapentine-loaded poly(lactic acid-co-glycolic acid) (PLGA) microspheres (RPMs) for the treatment of osteoarticular tuberculosis to avoid critical side effects caused by oral regimens of antibiotics or intravenous antibiotics. The RPMs were spherical with rough surfaces, and elevated amounts of rifapentine in the formulation markedly increased the particle size and drug loading, while decreased the size distribution and entrapment efficiency. The highest drug loading and encapsulation efficiency of RPMs were 23.93%±3.93% and 88.49%±8.49%, respectively. After the initial rapid drug release, the release rate gradually decreased, and approximately 80% of the encapsulated rifapentine was released after 30 days of incubation. Moreover, RPMs could effectively inhibit the growth of Staphylococcus aureus. With increasing rifapentine content, the inhibition zones were continuously enlarged while the minimal inhibitory concentration values decreased. These results suggested that RPMs were bioactive and controlled release delivery systems for the treatment of osteoarticular tuberculosis.
authors.affiliation: Department of Orthopedics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China.
authors.forename: Jun
authors.initials: J
authors.lastname: Wu
authors.affiliation: Research Center for Nano-Biomaterials, Analytical and Testing Center, Sichuan University, Chengdu, Sichuan, People's Republic of China.
authors.forename: Yi
authors.initials: Y
authors.lastname: Zuo
authors.affiliation: Department of Orthopedics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China.
authors.forename: Yunjiu
authors.initials: Y
authors.lastname: Hu
authors.affiliation: Research Center for Nano-Biomaterials, Analytical and Testing Center, Sichuan University, Chengdu, Sichuan, People's Republic of China.
authors.forename: Jian
authors.initials: J
authors.lastname: Wang
authors.affiliation: Research Center for Nano-Biomaterials, Analytical and Testing Center, Sichuan University, Chengdu, Sichuan, People's Republic of China.
authors.forename: Jidong
authors.initials: J
authors.lastname: Li
authors.affiliation: Department of Orthopedics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China.
authors.forename: Bo
authors.initials: B
authors.lastname: Qiao
authors.affiliation: Department of Orthopedics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China.
authors.forename: Dianming
authors.initials: D
authors.lastname: Jiang
mesh_terms: D016503:Drug Delivery Systems; D019344:Lactic Acid / Q000737:chemistry*; D008826:Microbial Sensitivity Tests; D008863:Microspheres; D010316:Particle Size; D011100:Polyglycolic Acid / Q000737:chemistry*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D012293:Rifampin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D013211:Staphylococcus aureus / Q000187:drug effects / Q000254:growth & development; D013499:Surface Properties; D014394:Tuberculosis, Osteoarticular / Q000188:drug therapy* / Q000382:microbiology
chemical_list: D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D012293:Rifampin; C018421:rifapentine
keywords: PLGA microspheres; Staphylococcus aureus; antibacterial; antitubercular drugs; chemotherapy; in vitro
references.citation: Mol Pharm. 2012 May 7;9(5):1489-501
references.pmid: 22482935
references.citation: Int J Pharm. 2007 Jun 29;338(1-2):133-41
references.pmid: 17363204
references.citation: Int J Pharm. 2011 Aug 30;415(1-2):34-52
references.pmid: 21640806
references.citation: Int J Pharm. 2011 Jul 29;414(1-2):112-7
references.pmid: 21596123
references.citation: Tuberculosis (Edinb). 2010 Mar;90(2):94-118
references.pmid: 20236863
references.citation: Colloids Surf B Biointerfaces. 2011 Oct 15;87(2):293-8
references.pmid: 21700434
references.citation: Polymers (Basel). 2011 Sep 1;3(3):1377-1397
references.pmid: 22577513
references.citation: J Mater Sci Mater Med. 2012 Jan;23(1):89-98
references.pmid: 22183789
references.citation: AAPS PharmSciTech. 2001;2(3):E10
references.pmid: 14727869
references.citation: Int J Infect Dis. 2012 Nov;16(11):e774-8
references.pmid: 22940279
references.citation: Int J Pharm. 2002 Jun 4;239(1-2):37-46
references.pmid: 12052689
references.citation: Pulm Pharmacol Ther. 2014 Apr;27(2):197-207
references.pmid: 23916767
references.citation: J Control Release. 2010 Mar 19;142(3):339-46
references.pmid: 19951729
references.citation: Clin Infect Dis. 1993 Aug;17(2):204-9
references.pmid: 8399868
references.citation: J Pharm Sci. 1997 Dec;86(12):1464-77
references.pmid: 9423163
references.citation: Arch Pharm Res. 2004 Jan;27(1):1-12
references.pmid: 14969330
references.citation: J Control Release. 2012 Jul 20;161(2):505-22
references.pmid: 22353619
references.citation: Expert Opin Drug Deliv. 2014 Mar;11(3):421-31
references.pmid: 24397259